Can less radiation be enough? new trial aims to cut side effects for HPV-linked throat cancer
NCT ID NCT02945631
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This phase II trial is testing whether a lower dose of chemoradiotherapy, given after initial chemotherapy, can effectively treat locally advanced HPV-positive oropharynx cancer while reducing long-term side effects. The study involves 43 participants and tracks how long the cancer stays under control, overall survival, and toxicity rates. The goal is to find a less harsh treatment option for this specific type of throat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HPV POSITIVE OROPHARYNX CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemoradiotherapy (lower-dose radiation with chemotherapy)
What this could lead to
If successful, this could show that a lower dose of chemoradiotherapy is safe and effective for HPV-positive throat cancer, reducing long-term side effects.
What could go wrong
This is a small, early-phase trial with only 43 participants, so results may not apply to all patients. The lower dose might not control the cancer as well as standard treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.